knowledge -WSS

knowledge

author：leisure time 2025-10-01 04:13:56 - browse：1519

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Readout Newsletter: Merck, Vertex, and Viking updates

WSS

Why getting cancer drugs just got harder for rural patients

Patient advocates debate FDA's accelerated approval process

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Eliminate the waiting period for sterilization covered by Medicaid

FDA's naming rule on biosimilars has undermined competition

Wikipedia

knowledge

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Why getting cancer drugs just got harder for rural patients

Walensky prepares to leave CDC — and Congress — behind

Vertex Pharmaceuticals may move headquarters in Boston

Activists slam private health insurers over coverage restrictions

Pfizer highlights cancer drugs it thinks could reignite investor interest

Novavax promises a turnaround & Lilly roils the obesity market

Medical device lobby: We're tired of waiting on Medicare coverage

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

leisure time

Why the world’s most expensive drug might be worth the price

ALS groups 'won't be played again' by the FDA, drug sponsors

Abortion pill case raises question: who can sue the FDA?

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Supreme Court mifepristone arguments center on docs' right to sue

Clinical trials giant ICON acquires HumanFirst

focus

explore

focus

focus